These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 35246810)
1. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810 [TBL] [Abstract][Full Text] [Related]
2. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114 [TBL] [Abstract][Full Text] [Related]
3. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900 [TBL] [Abstract][Full Text] [Related]
4. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804 [TBL] [Abstract][Full Text] [Related]
5. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals? Williams AD; Dang CT; Sevilimedu V; Morrow M; Barrio AV Ann Surg Oncol; 2022 Dec; 29(13):8002-8011. PubMed ID: 35871672 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563 [TBL] [Abstract][Full Text] [Related]
8. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877 [TBL] [Abstract][Full Text] [Related]
9. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233 [TBL] [Abstract][Full Text] [Related]
10. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369 [TBL] [Abstract][Full Text] [Related]
11. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment. Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Boughey JC; Hoskin TL; Goetz MP Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation? Cerbelli B; Botticelli A; Pisano A; Campagna D; De Vincentiis L; Pernazza A; Frusone F; Scavina P; Monti M; Fortunato L; Costarelli L; d'Amati G Breast J; 2019 Mar; 25(2):273-277. PubMed ID: 30734420 [TBL] [Abstract][Full Text] [Related]
14. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study. Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807 [TBL] [Abstract][Full Text] [Related]
15. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy. Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202 [TBL] [Abstract][Full Text] [Related]
16. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy? Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123 [TBL] [Abstract][Full Text] [Related]
17. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. Gentile LF; Plitas G; Zabor EC; Stempel M; Morrow M; Barrio AV Ann Surg Oncol; 2017 Dec; 24(13):3896-3902. PubMed ID: 28916978 [TBL] [Abstract][Full Text] [Related]
18. Surgical Axillary Staging Before Neoadjuvant Chemotherapy: Who Gets It and Why We Should Avoid It. Iles K; Strassle PD; Agala CB; Button J; Downs-Canner S Ann Surg Oncol; 2021 Oct; 28(10):5788-5797. PubMed ID: 34379251 [TBL] [Abstract][Full Text] [Related]
19. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528 [TBL] [Abstract][Full Text] [Related]
20. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? Mamtani A; Sevilimedu V; Le T; Morrow M; Barrio AV Cancer; 2022 Feb; 128(3):471-478. PubMed ID: 34597420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]